Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00223145 | Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone | PHASE3 | ACTIVE NOT_RECRUITING | 600 | — | — | Dec 1, 2000 | Dec 31, 2027 | Jan 27, 2025 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Androgen blockade for 6 months + Radiotherapy 70 Gy |
| Arm 2 | EXPERIMENTAL | Androgen blockade for 6 months + Radiotherapy 76 Gy |
| Arm 3 | ACTIVE_COMPARATOR | Radiotherapy alone with 76 Gy |
| Name | Type | Description |
|---|---|---|
| Radiotherapy 70 Gy | RADIATION | Radiotherapy to the prostate |
| Radiotherapy 76 Gy | RADIATION | Radiotherapy to the prostate |
| Androgen blockade | DRUG | Duration : 6 months |
Inclusion Criteria: * Patients with stage T1 or T2 untreated adenocarcinoma of the prostate, with a Gleason score that is less than or equal to 6, as well as a prostate-specific antigen (PSA) between 10-20 (intermediate risk) or patients with stage T1 or T2 untreated adenocarcinoma of the prostate,...